Persistent alopecia induced by vismodegib

Alkeraye, Salim; Maire, Cyril; Desmedt, E.; Templier, C.; Mortier, Laurent

doi:10.1111/bjd.13630

Cited by 28 publications

(17 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anticancer therapies such as vismodegib, 69 and immunotherapies, 70 have been reported to cause persistent alopecia after drug interruption or discontinuation. Chronic graft versus host diseases after stem cell transplants may induce both diffuse alopecia (15.6%), 31 and alopecia areata (in around 20%) 71 (Table I).…”

Section: Persistent Hair Changes Induced By Other Anticancer Therapiesmentioning

confidence: 99%

Hair disorders in cancer survivors

Freites-Martínez

Shapiro

Hurk

et al. 2019

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

With increasing survival rates across all cancers, survivors represent a growing population that is frequently affected by persistent or permanent hair growth disorders as a result of systemic therapies, radiotherapy, surgical procedures, and therapeutic transplants. These hair disorders include persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, endocrine therapy-induced alopecia and hirsutism, post-surgery alopecia and localized hypertrichosis, alopecia attributed to therapeutic transplants, and to novel anticancer therapies. The information contained in this continuing medical education article should facilitate a better understanding on hair disorders in cancer survivors, so that adequate support and therapies may be provided to cancer survivors.

show abstract

Section: Persistent Hair Changes Induced By Other Anticancer Therapiesmentioning

confidence: 99%

Hair disorders in cancer survivors

Freites-Martínez

Shapiro

Hurk

et al. 2019

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

“…Moreover, the AEs commonly observed in vismodegib-treated patients, including muscle spasms, ageusia/dysgeusia, alopecia, weight loss, and fatigue, lead to poor clinical outcomes because of the decreased quality of life and treatment discontinuation[143], and the more severe AEs can lead to death[144]. In some cases, treatment with vismodegib resulted in the development of squamous cell carcinoma[145], amenorrhea[146], and persistent alopecia[147]. Patient treated with vismodegib for one month can develop severe nausea, jaundice, and cholestasis with significantly elevated BUN, creatinine, and liver enzymes[148].…”

Section: Csc Signaling Pathways and Inhibitorsmentioning

confidence: 99%

Targeting cancer stem cells in drug discovery: Current state and future perspectives

Zhou

Sun

et al. 2019

WJSC

View full text Add to dashboard Cite

In recent decades, cancer stem cells (CSCs) have been increasingly identified in many malignancies. CSC-related signaling pathways and their functions provide new strategies for treating cancer. The aberrant activation of related signaling pathways ( e.g ., Wnt, Notch, and Hedgehog pathways) has been linked to multiple types of malignant tumors, which makes these pathways attractive targets for cancer therapy. CSCs display many characteristic features, such as self-renewal, differentiation, high tumorigenicity, and drug resistance. Therefore, there is an urgent need to develop new therapeutic strategies to target these pathways to control stem cell replication, survival, and differentiation. Notable crosstalk occurs among different signaling pathways and potentially leads to compensatory escape. Therefore, multitarget inhibitors will be one of the main methods to overcome the drug resistance of CSCs. Many small molecule inhibitors of components of signaling pathways in CSCs have entered clinical trials, and some inhibitors, such as vismodegib, sonidegib, and glasdegib, have been approved. Tumor cells are susceptible to sonidegib and vismodegib resistance due to mutations in the Smo protein. The signal transducers and activators of transcription 3 (STAT3) inhibitor BBI608 is being evaluated in a phase III trial for a variety of cancers. Structural derivatives of BBI608 are the main focus of STAT3 inhibitor development, which is another strategy for CSC therapy. In addition to the potential pharmacological inhibitors targeting CSC-related signaling pathways, other methods of targeting CSCs are available, such as nano-drug delivery systems, mitochondrion targeting, autophagy, hyperthermia, immunotherapy, and CSC microenvironment targeting. In addition, we summarize the latest advances in the clinical development of agents targeting CSC-related signaling pathways and other methods of targeting CSCs.

show abstract

“…Alopecia typically develops gradually, and, in some cases, can be delayed and actually occur after HPI treatment has been halted. Alopecia associated with HPI treatment can also be persistent and, in rare cases, might be permanent [64]. Supportive care includes the identification of comorbidities that might contribute to alopecia and use of minoxidil, oral dihydrotestosterone inhibitors (i.e., spironolactone, finasteride), and camouflaging methods (i.e., sprays, powders, hairpieces, and wigs) ( Fig.…”

Section: Alopeciamentioning

confidence: 99%

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Dréno²,

et al. 2016

View full text Add to dashboard Cite

Vismodegib and sonidegib are Hedgehog pathway inhibitors (HPIs) approved for treatment of patients with advanced basal cell carcinoma. The adverse events (AEs) associated with these therapies can impact clinical outcomes as a result of decreased quality of life and treatment discontinuation. The incidence, clinical presentation, putative mechanisms, and management strategies for AEs related to administration of HPIs are described in this article.

show abstract

Persistent alopecia induced by vismodegib

Cited by 28 publications

References 4 publications

Hair disorders in cancer survivors

Hair disorders in cancer survivors

Targeting cancer stem cells in drug discovery: Current state and future perspectives

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Contact Info

Product

Resources

About